View Item 

Show simple item record

Merlin immunohistochemistry is useful in diagnosis of tumours within the spectrum of biphasic hyalinizing psammomatous renal cell carcinoma

dc.contributor.authorCollins, Katrina
dc.contributor.authorHwang, Michael
dc.contributor.authorAntic, Tatjana
dc.contributor.authorPaintal, Ajit
dc.contributor.authorArgani, Pedram
dc.contributor.authorMatoso, Andres
dc.contributor.authorGopinath, Arun
dc.contributor.authorBaskovich, Brett
dc.contributor.authorMehra, Rohit
dc.contributor.authorWilliamson, Sean R.
dc.contributor.authorIdrees, Muhammad T.
dc.contributor.authorBarletta, Justine A.
dc.contributor.authorAnderson, William J.
dc.contributor.authorHirsch, Michelle S.
dc.contributor.authorHornick, Jason L.
dc.contributor.authorAcosta, Andres M.
dc.date.accessioned2022-11-09T21:20:14Z
dc.date.available2023-12-09 16:20:08en
dc.date.available2022-11-09T21:20:14Z
dc.date.issued2022-11
dc.identifier.citationCollins, Katrina; Hwang, Michael; Antic, Tatjana; Paintal, Ajit; Argani, Pedram; Matoso, Andres; Gopinath, Arun; Baskovich, Brett; Mehra, Rohit; Williamson, Sean R.; Idrees, Muhammad T.; Barletta, Justine A.; Anderson, William J.; Hirsch, Michelle S.; Hornick, Jason L.; Acosta, Andres M. (2022). "Merlin immunohistochemistry is useful in diagnosis of tumours within the spectrum of biphasic hyalinizing psammomatous renal cell carcinoma." Histopathology (5): 577-586.
dc.identifier.issn0309-0167
dc.identifier.issn1365-2559
dc.identifier.urihttps://hdl.handle.net/2027.42/175126
dc.publisherWiley Periodicals, Inc.
dc.subject.otherrenal cell carcinoma
dc.subject.othermutation
dc.subject.othermerlin
dc.subject.otherNF2
dc.subject.otherrenal neoplasm
dc.titleMerlin immunohistochemistry is useful in diagnosis of tumours within the spectrum of biphasic hyalinizing psammomatous renal cell carcinoma
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMicrobiology and Immunology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175126/1/his14731.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175126/2/his14731_am.pdf
dc.identifier.doi10.1111/his.14731
dc.identifier.sourceHistopathology
dc.identifier.citedreferenceMalouf GG, Flippot R, Dong Y et al. Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. Sci. Rep. 2020; 10; 701.
dc.identifier.citedreferencePal SK, Choueiri TK, Wang K et al. Characterization of clinical cases of collecting duct carcinoma of the kidney assessed by comprehensive genomic profiling. Eur. Urol. 2016; 70; 516 – 521.
dc.identifier.citedreferenceChang LS, Akhmametyeva EM, Wu Y, Zhu L, Welling DB. Multiple transcription initiation sites, alternative splicing, and differential polyadenylation contribute to the complexity of human neurofibromatosis 2 transcripts. Genomics 2002; 79; 63 – 76.
dc.identifier.citedreferenceSchmucker B, Tang Y, Kressel M. Novel alternatively spliced isoforms of the neurofibromatosis type 2 tumor suppressor are targeted to the nucleus and cytoplasmic granules. Hum. Mol. Genet. 1999; 8; 1561 – 1570.
dc.identifier.citedreferenceWang G, Amin MB, Grossmann P et al. Renal cell tumor with sex-cord/gonadoblastoma-like features: Analysis of 6 cases. Virchows Arch. 2022; 480; 349 – 358.
dc.identifier.citedreferenceYakirevich E, Pavlick DC, Perrino CM et al. NF2 tumor suprressor gene inactivation in advanced papillary renal cell carcinoma. Am. J. Surg. Pathol. 2021; 45; 716 – 718.
dc.identifier.citedreferenceLobo J, Ohashi R, Amin MB, Berney DM, Compérat EM, Cree IA, Gill AJ, Hartmann A, Menon S, Netto GJ, Raspollini MR, Rubin MA, Tan PH, Tickoo SK, Tsuzuki T, Turajlic S, Zhou M, Srigley JR, Moch H WHO 2022 landscapre of papillary and chromophobe renal cell carcinoma. Histopathology. 2022. Online ahead of print.
dc.identifier.citedreferenceSrigley JR, Delahunt B, Eble JN et al. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. Am. J. Surg. Pathol. 2013; 37; 1469 – 1489.
dc.identifier.citedreferenceGopinath A, Mubeen A, Jamal M, Mohammed I, Gopireddy DR, Baskovich B. Biphasic hyalinizing Psammomatous renal cell carcinoma: Another provisional entity emerging from the papillary renal cell carcinoma Pandora’s box. Int. J. Surg. Pathol. 2021; 29; 783 – 787.
dc.identifier.citedreferenceWang XT, Xia QY, Fang R et al. Clinicopathological and molecular characterization of biphasic hyalinizing psammomatous renal cell carcinoma: Further support for the newly proposed entity. Hum. Pathol. 2022; 123; 102 – 112.
dc.identifier.citedreferencePaintal A, Tjota MY, Wang P et al. NF2-mutated renal carcinomas have common morphologic features which overlap with biphasic hyalinizing Psammomatous renal cell carcinoma: A comprehensive study of 14 cases. Am. J. Surg. Pathol. 2022; 46; 617 – 627.
dc.identifier.citedreferenceArgani P, Reuter VE, Eble JN et al. Biphasic hyalinizing Psammomatous renal cell carcinoma (BHP RCC): A distinctive neoplasm associated with somatic NF2 mutations. Am. J. Surg. Pathol. 2020; 44; 901 – 916.
dc.identifier.citedreferencePetrilli AM, Fernández-Valle C. Role of Merlin/NF2 inactivation in tumor biology. Oncogene 2016; 35; 537 – 548.
dc.identifier.citedreferenceCooper J, Giancotti FG. Molecular insights into NF2/Merlin tumor suppressor function. FEBS Lett. 2014; 588; 2743 – 2752.
dc.identifier.citedreferenceChapel DB, Hornick JL, Barlow J, Bueno R, Sholl LM. Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma. Mod. Pathol. 2022. Online ahead of print.
dc.identifier.citedreferenceChen YB, Xu J, Skanderup AJ et al. Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. Nat. Commun. 2016; 7; 13131.
dc.identifier.citedreferenceMehra R, Vats P, Cieslik M et al. Biallelic alteration and dysregulation of the hippo pathway in mucinous tubular and spindle cell carcinoma of the kidney. Cancer Discov. 2016; 6; 1258 – 1266.
dc.identifier.citedreferenceRybarczyk A, Klacz J, Wronska A, Matuszewski M, Kmiec Z, Wierzbicki PM. Overexpression of the YAP1 oncogene in clear cell renal cell carcinoma is associated with poor outcome. Oncol. Rep. 2017; 38; 427 – 439.
dc.identifier.citedreferenceZhang N, Bai H, David KK et al. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev. Cell 2010; 19; 27 – 38.
dc.identifier.citedreferenceGleeson JP, Nikolovski I, Dinatale R et al. Comprehensive molecular characterization and response to therapy in fumarate hydratase-deficient renal cell carcinoma. Clin. Cancer Res. 2021; 27; 2910 – 2919.
dc.identifier.citedreferenceLinehan WM, Spellman PT, Ricketts CJ et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N. Engl. J. Med. 2016; 374; 135 – 145.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
his14731.pdf
Size:
10.98MB
Format:
PDF
View/Open
Name:
his14731_am.pdf
Size:
28.60MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.